Bio Techne Net Worth
Bio Techne Net Worth Breakdown | TECH |
Bio Techne Net Worth Analysis
Bio Techne's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Bio Techne's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Bio Techne's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Bio Techne's net worth analysis. One common approach is to calculate Bio Techne's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Bio Techne's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Bio Techne's net worth. This approach calculates the present value of Bio Techne's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Bio Techne's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Bio Techne's net worth. This involves comparing Bio Techne's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Bio Techne's net worth relative to its peers.
Enterprise Value |
|
To determine if Bio Techne is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Bio Techne's net worth research are outlined below:
| Bio Techne Corp has a poor financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are owned by institutional investors | |
| On 22nd of November 2024 Bio Techne paid $ 0.08 per share dividend to its current shareholders | |
| Latest headline from finance.yahoo.com: BIO-TECHNE TO PRESENT AT THE CITI 2024 GLOBAL HEALTHCARE CONFERENCE |
Bio Techne Quarterly Good Will |
|
Bio Techne uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Bio Techne Corp. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Bio Techne's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 1st of February 2024 Upcoming Quarterly Report | View | |
| 1st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 13th of August 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 30th of June 2023 Last Financial Announcement | View |
Know Bio Techne's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Bio Techne is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Bio Techne Corp backward and forwards among themselves. Bio Techne's institutional investor refers to the entity that pools money to purchase Bio Techne's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Mackenzie Investments | 2024-09-30 | 2.9 M | Bank Of New York Mellon Corp | 2024-06-30 | 2.7 M | Mairs & Power Inc | 2024-09-30 | 2.7 M | Champlain Investment Partners, Llc | 2024-09-30 | 2.6 M | Massachusetts Financial Services Company | 2024-09-30 | 2.6 M | Macquarie Group Ltd | 2024-06-30 | 2.5 M | Brown Capital Management, Llc | 2024-09-30 | 2.1 M | Marshall Wace Asset Management Ltd | 2024-06-30 | 2 M | Norges Bank | 2024-06-30 | 1.9 M | Vanguard Group Inc | 2024-09-30 | 18.3 M | Blackrock Inc | 2024-06-30 | 15 M |
Follow Bio Techne's market capitalization trends
The company currently falls under 'Large-Cap' category with a current market capitalization of 11.98 B.Market Cap |
|
Project Bio Techne's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.14 | 0.16 | |
| Return On Capital Employed | 0.08 | 0.08 | |
| Return On Assets | 0.06 | 0.06 | |
| Return On Equity | 0.08 | 0.08 |
When accessing Bio Techne's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Bio Techne's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Bio Techne's profitability and make more informed investment decisions.
Evaluate Bio Techne's management efficiency
Bio Techne Corp has return on total asset (ROA) of 0.0555 % which means that it generated a profit of $0.0555 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0729 %, meaning that it created $0.0729 on every $100 dollars invested by stockholders. Bio Techne's management efficiency ratios could be used to measure how well Bio Techne manages its routine affairs as well as how well it operates its assets and liabilities. The Bio Techne's current Return On Tangible Assets is estimated to increase to 0.16, while Return On Capital Employed is projected to decrease to 0.08. As of now, Bio Techne's Other Current Assets are increasing as compared to previous years. The Bio Techne's current Total Current Assets is estimated to increase to about 648.3 M, while Other Assets are projected to decrease to under 8.8 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 13.12 | 13.77 | |
| Tangible Book Value Per Share | 3.74 | 3.92 | |
| Enterprise Value Over EBITDA | 37.25 | 39.11 | |
| Price Book Value Ratio | 5.46 | 6.78 | |
| Enterprise Value Multiple | 37.25 | 39.11 | |
| Price Fair Value | 5.46 | 6.78 | |
| Enterprise Value | 2.2 B | 2.3 B |
Bio Techne showcases strong leadership that adapts to market changes and drives innovation. Our analysis explores how this adaptability affects the stock's investment appeal.
Enterprise Value Revenue 10.4009 | Revenue 1.2 B | Quarterly Revenue Growth 0.045 | Revenue Per Share 7.424 | Return On Equity 0.0729 |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bio Techne insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bio Techne's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Bio Techne insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Kim Kelderman over two months ago Acquisition by Kim Kelderman of 1492 shares of Bio Techne at 66.97 subject to Rule 16b-3 | ||
Kim Kelderman over three months ago Acquisition by Kim Kelderman of 1492 shares of Bio Techne at 66.97 subject to Rule 16b-3 | ||
Klimovsky Judith V over six months ago Insider Trading | ||
Harold Wiens over a year ago Bio Techne exotic insider transaction detected | ||
Rupert Vessey over a year ago Acquisition by Rupert Vessey of 1625 shares of Bio Techne subject to Rule 16b-3 | ||
Harold Wiens over a year ago Bio Techne exotic insider transaction detected | ||
Harold Wiens over a year ago Bio Techne exotic insider transaction detected |
Bio Techne Corporate Filings
13A | 14th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
13A | 8th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
10Q | 5th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 30th of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Bio Techne Earnings per Share Projection vs Actual
Bio Techne Corporate Management
| Lynne Hohlfeld | Senior Division | Profile | |
| Luca Cicchetti | Managing Director | Profile | |
| Brenda JD | Gen VP | Profile | |
| Martin Wirtz | Senior Development | Profile | |
| Cheryl Bethune | Senior Officer | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Bio Techne Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Techne. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Techne listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.32) | Dividend Share 0.32 | Earnings Share 0.95 | Revenue Per Share 7.424 | Quarterly Revenue Growth 0.045 |
The market value of Bio Techne Corp is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Techne's value that differs from its market value or its book value, called intrinsic value, which is Bio Techne's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Techne's market value can be influenced by many factors that don't directly affect Bio Techne's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bio Techne's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Techne is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Techne's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.